Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $308,000 Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 694 shares of the pharmaceutical company’s stock after acquiring an additional 34 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Vertex Pharmaceuticals were worth $308,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in VRTX. Czech National Bank lifted its holdings in Vertex Pharmaceuticals by 6.2% during the 4th quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock valued at $22,486,000 after purchasing an additional 3,260 shares during the last quarter. Whalen Wealth Management Inc. bought a new position in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $662,000. Concord Wealth Partners boosted its holdings in shares of Vertex Pharmaceuticals by 32.6% in the 4th quarter. Concord Wealth Partners now owns 3,508 shares of the pharmaceutical company’s stock worth $1,413,000 after acquiring an additional 862 shares in the last quarter. Mizuho Securities USA LLC increased its holdings in Vertex Pharmaceuticals by 289.0% during the 3rd quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock valued at $35,994,000 after purchasing an additional 57,497 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in Vertex Pharmaceuticals by 19.4% in the 4th quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company’s stock valued at $137,783,000 after purchasing an additional 55,739 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Stock Down 2.5 %

Shares of NASDAQ VRTX opened at $469.32 on Monday. The company has a fifty day moving average price of $435.87 and a 200 day moving average price of $462.49. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Jefferies Financial Group upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the company from $500.00 to $550.00 in a research note on Monday, December 9th. Oppenheimer downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. Scotiabank increased their price target on shares of Vertex Pharmaceuticals from $430.00 to $433.00 and gave the company a “sector perform” rating in a research note on Friday, January 31st. Barclays dropped their price objective on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating for the company in a research report on Friday, December 20th. Finally, Canaccord Genuity Group lifted their target price on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a research note on Wednesday, November 6th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $502.58.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.